Allergy Therapeutics (AGY) — Net Asset Momentum
Allergy Therapeutics (AGY) recorded a net asset momentum of -860.1% as of June 2025, with net assets of GBX-28.19 Million GBX. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. See Allergy Therapeutics liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
YoY Momentum
Current Net Assets
Years of Data
Country
Allergy Therapeutics Net Asset Momentum (2002–2025)
This chart tracks Allergy Therapeutics's year-over-year net asset growth across 24 annual reporting periods from 2002 to 2025. The most recent momentum reading is -860.1%, with net assets of GBX-28.19 Million GBX as of June 2025. Read Allergy Therapeutics balance sheet liabilities for a breakdown of total debt and financial obligations.
Annual Net Asset History for Allergy Therapeutics (2002–2025)
The table below shows the complete annual net asset history for Allergy Therapeutics from 2002 to 2025, covering 24 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and broader valuation context, see market value of Allergy Therapeutics.
| Year | Net Assets (GBX) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2025 | GBX-28.19 Million | GBX67.54 Million | GBX95.74 Million | ▼ -860.1% |
| 2024 | GBX3.71 Million | GBX64.83 Million | GBX61.12 Million | ▲ +79.5% |
| 2023 | GBX2.07 Million | GBX66.77 Million | GBX64.70 Million | ▼ -94.5% |
| 2022 | GBX37.77 Million | GBX72.95 Million | GBX35.18 Million | ▼ -22.2% |
| 2021 | GBX48.53 Million | GBX88.09 Million | GBX39.55 Million | ▲ +10.9% |
| 2020 | GBX43.78 Million | GBX86.22 Million | GBX42.44 Million | ▲ +16.6% |
| 2019 | GBX37.56 Million | GBX68.50 Million | GBX30.94 Million | ▲ +63.1% |
| 2018 | GBX23.03 Million | GBX51.02 Million | GBX27.98 Million | ▼ -23.1% |
| 2017 | GBX29.96 Million | GBX57.18 Million | GBX27.22 Million | ▼ -1.2% |
| 2016 | GBX30.32 Million | GBX56.68 Million | GBX26.36 Million | ▼ -12.0% |
| 2015 | GBX34.47 Million | GBX50.70 Million | GBX16.23 Million | ▲ +128.7% |
| 2014 | GBX15.07 Million | GBX28.40 Million | GBX13.32 Million | ▲ +2.8% |
| 2013 | GBX14.67 Million | GBX28.96 Million | GBX14.29 Million | ▲ +0.5% |
| 2012 | GBX14.59 Million | GBX27.75 Million | GBX13.16 Million | ▲ +582.2% |
| 2011 | GBX2.14 Million | GBX30.62 Million | GBX28.48 Million | ▼ -45.0% |
| 2010 | GBX3.89 Million | GBX29.11 Million | GBX25.23 Million | ▲ +116.8% |
| 2009 | GBX-23.18 Million | GBX22.08 Million | GBX45.25 Million | ▼ -105.3% |
| 2008 | GBX-11.29 Million | GBX23.18 Million | GBX34.47 Million | ▼ -231.3% |
| 2007 | GBX8.60 Million | GBX23.99 Million | GBX15.40 Million | ▼ -73.7% |
| 2006 | GBX32.70 Million | GBX37.88 Million | GBX5.18 Million | ▲ +62.8% |
| 2005 | GBX20.08 Million | GBX26.66 Million | GBX6.58 Million | ▲ +183.8% |
| 2004 | GBX7.08 Million | GBX11.23 Million | GBX4.16 Million | ▲ +27.6% |
| 2003 | GBX5.55 Million | GBX11.15 Million | GBX5.60 Million | ▲ +226.1% |
| 2002 | GBX-4.40 Million | GBX9.68 Million | GBX14.07 Million | — |